Once thought to be purely an endocrine disorder, a more modern understanding of insulin resistance and glycemic regulation has revealed that prediabetes, type 1 and type 2 diabetes are hugely related to cardiometabolic disease and its many comorbidities. As the understanding of how diabetes is related to conditions like obesity and heart failure grows, more therapeutic targets are being identified, showing promise for many new treatments.
CME/CE Activities
News Digest
Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD
Dr. Salvatore Carbone is professor in the Department of Kinesiology & Health Sciences, College of Humanities & Sciences at the Virginia Commonwealth University. Can you
Cardiometabolic Health Congress (CMHC) Launches Focused Digital Education Hubs
Cardiometabolic health education leader CMHC announced that its digital education has been streamlined into 12 hubs organized by therapeutic or clinical topics for focused learning
Cardiometabolic Health Congress Hosts 2023 Women’s Masterclass in California
In August 2023, Cardiometabolic Health Congress will host the annual Women’s Cardiometabolic Health and Wellness Masterclass at the Laguna Cliffs Marriott Resort & Spa Informed
Care in (un)Common Settings with Dr. Keith C. Ferdinand
Cardiometabolic Health Congress (CMHC) sat down with Dr. Keith C. Ferdinand, the Gerald S. Berenson Endowed Chair in preventive cardiology at Tulane School of Medicine
Updated 2023 ADA Standards of Care
The new ADA guideline contains updated guidance for clinicians who care for the estimated 100 million patients in the U.S. with prediabetes or diabetes.
Identifying and Treating Severe Hypoglycemia in Pediatric Patients with Diabetes
Hypoglycemia is estimated to affect 47-83% of patients with diabetes and is a common side effect of several diabetes medications, but is particularly associated with
Should Diabetes Management be More Adipose-Centric?
This complimentary activity was developed by Neha Agarwal, PhD, Senior Clinical Manager for Cardiometabolic Health Congress (CMHC). It is supported by an educational grant from Lilly
FDA Approves First SGLT1/SGLT2 Inhibitor Sotagliflozin
The U.S. Food and Drug Administration (FDA) announced on May 26, 2023, it had approved the once-daily oral tablet sotagliflozin to reduce the risk of
10 Cardiorenal Stories to Watch
The experts behind Cardiometabolic Health Congress have identified 10 stories in cardiorenal medicine to watch in 2023.
Sanofi Joins Lilly and Novo to Cut Insulin Prices
Sanofi was the last of three pharmaceutical goliaths to announce they’d make good on their long-spoken promise to lower the price of their insulin.
Genetics Link Migraine and Blood Sugar
Research published on Feb. 20, 2023, by Rafiqul Islam, PhD, and colleagues from Queensland University of Technology may have uncovered a concrete link between blood
Lilly Cuts Insulin Prices
In an era when health care and pharmaceutical prices continue to trend upwards, Eli Lilly made a historic announcement on Wednesday, March 1, 2023, stating
Tirzepatide For Weight Loss
Eli LIlly’s tirzepatide (Monjaro) could become the most popular weight-loss drug ever if approved, but there are significant concerns about if it will be affordable
Rybelsus Wins FDA Label Update
On Jan. 12, 2023, Novo Nordisk announced the US Food and Drug Administration (FDA) approved a label update to permit first-line use of oral semaglutide
2022 News in Review: Top 10 Stories in Cardiorenal Metabolic Health
The experts at Cardiometabolic Health Congress (CMHC) have selected the TOP 10 developments, approvals, news, and findings from 2022 that impact the field of cardiorenal
FDA Approves Insulin Biosimilar Rezvoglar
The FDA has approved Eli Lilly’s insulin glargine-aglr, sold under the brand name Rezvoglar.
The Buzz About Honey
Researchers have found consuming certain forms of honey may improve glycemic control and lipid levels when part of a healthy dietary pattern.
FDA Approves First Drug To Delay Onset of Type 1 Diabetes
For the first time in history, the FDA has approved a therapy that addresses the autoimmunity behind T1D — not just the symptoms of the
Expert Highlights and Perspectives
MD
DUAL GLP-1/GIP AGONISTS: ARE THEY THE NEXT BIG THING IN DIABETES TREATMENT
(Recorded April 2022)
MD
HOW CAN WE CONVERGE THE GLUCOCENTRIC AND CARDIO-RENAL RISK MANAGEMENT IN DIABETES PATIENTS
(Recorded April 2022)
MD
MD
MD, PhD
MD, PhD
MD
MD
MD
MD
MD
Drug Pipeline
Drug Pipeline Coming Soon
#C1E5E9
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
#C1E5E9
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
#C1E5E9
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.